Cialis (Tadalafil) and Levothyroxine Interaction: Safety, Risks, and Clinical Guidance

Tadalafil (Cialis) belongs to the phosphodiesterase type 5 (PDE5) inhibitor class and is approved for treating erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension, the latter under the brand name Adcirca. Levothyroxine (Synthroid, Levoxyl, Tirosint, and generics) is a synthetic form of thyroxine (T4) prescribed for hypothyroidism. Patients frequently use both medications concurrently because hypothyroidism and erectile dysfunction often occur together in the same individual, rather than because either medication addresses the other's primary indication.

There is no known clinically significant pharmacokinetic or pharmacodynamic interaction between tadalafil and levothyroxine. Neither the FDA-approved tadalafil label nor the FDA-approved levothyroxine label lists the other as a contraindication, precaution, or drug-interaction concern. Tadalafil is metabolized mainly through hepatic CYP3A4; levothyroxine is cleared through deiodination and hepatic conjugation pathways that do not overlap with tadalafil's metabolism. No dose adjustment of either drug is required solely because the other is present in the regimen.

The useful clinical question is not whether these two drugs interact directly (the evidence says they do not), but whether the way people actually take them, particularly the timing of levothyroxine relative to food and other pills, and the presence of other medications in the same regimen that do interact with tadalafil, ends up undermining treatment that each drug is separately meant to support.

The core answer, stated plainly

Tadalafil and levothyroxine do not share a metabolic pathway, and no regulatory label, drug-interaction database, or published pharmacology describes a direct interaction between them. The practical risk in this combination is not pharmacologic overlap but timing: levothyroxine's absorption is sensitive to food, coffee, calcium, iron, and antacids, so it should still be taken on an empty stomach, separated from other substances by the interval a prescriber or pharmacist recommends (commonly 30 to 60 minutes before food, longer for calcium or iron). Tadalafil has no such restriction and can be taken with or without food. Because untreated or poorly controlled hypothyroidism is itself associated with erectile dysfunction and low libido, correcting thyroid status is a reasonable first step before assuming a PDE5 inhibitor is the long-term answer.

What is established, what is plausible, what is not established

Established, from FDA labeling and basic pharmacology:

• Tadalafil is metabolized predominantly by CYP3A4; levothyroxine is not a substrate, inhibitor, or inducer of CYP3A4 or related hepatic enzymes. This is consistent with the mechanism sections of both FDA labels.
• Tadalafil is contraindicated with organic nitrates because of the risk of severe hypotension. This is unrelated to thyroid status but matters in a patient's full medication list.
• Levothyroxine has a narrow therapeutic index and well-documented absorption interference from calcium, iron, proton pump inhibitors, and some foods and beverages; standard practice is to take it fasting, separated from other oral medications and supplements.

Plausible but not established by a specific study in this pairing:

• Correcting hypothyroidism can improve erectile function in some men, based on the general clinical literature on thyroid-sexual function overlap. The magnitude of benefit, and which patients will improve versus still need a PDE5 inhibitor, is not something this article can quantify with a verified number; treat any specific percentage you encounter elsewhere as a claim to check against the primary study before repeating it to a patient.
• A patient who is inadvertently over-replaced on levothyroxine (iatrogenic subclinical or overt hyperthyroidism) may have a faster resting heart rate and altered hemodynamics, and adding a vasodilator like tadalafil in that state is a theoretical amplifier of hypotension risk. This is physiologically reasonable but has not been demonstrated as a measured clinical interaction between these two specific drugs.

Not established:

• No published pharmacokinetic study specifically measuring tadalafil levels with concurrent levothyroxine, or vice versa, was identified for this review. The absence of an interaction signal in labeling and interaction databases is meaningful, but it is an absence of evidence for harm, not a dedicated interaction trial.
• Claims quantifying exact prevalence of ED in hypothyroid men, exact percentage reductions in T4 absorption from coffee, or exact percentage increases in tadalafil AUC with specific CYP3A4 inhibitors should be verified against the primary literature before being cited as precise figures. This draft intentionally avoids repeating specific numbers that could not be checked against a confirmed source.

Why the mechanisms do not overlap

Tadalafil is metabolized in the liver, primarily by CYP3A4, to an inactive catechol metabolite. Levothyroxine is deiodinated peripherally and conjugated hepatically through glucuronidation and sulfation pathways that are distinct from the CYP3A4 system. Because levothyroxine does not meaningfully inhibit or induce CYP3A4, it does not change how quickly tadalafil is cleared, and tadalafil does not alter levothyroxine's deiodination or conjugation. This is the pharmacologic basis for classifying the pair as low interaction risk, and it is consistent with both drugs' FDA labeling, which does not flag the other as a concern.

Timing: the practical issue that actually matters

Levothyroxine absorption is reduced by food, coffee, calcium and iron supplements, and acid-reducing medications. Standard guidance from thyroid specialty societies is to take levothyroxine on an empty stomach and to separate it from calcium or iron by a longer interval than from a typical meal; ask a pharmacist for the specific separation interval recommended for your formulation, since brand and generic levothyroxine products can differ. Tadalafil is not known to alter gastric pH or bind divalent cations, so it is not part of this absorption-interference list, and the tadalafil label states that food does not meaningfully change its absorption.

A practical approach many prescribers use:

• Take levothyroxine first thing in the morning, fasting, with water only.
• Take tadalafil at whatever time suits its use: on-demand dosing before anticipated sexual activity, or at a consistent daily time if using the low-dose regimen approved for daily use.
• Do not shift levothyroxine to evening dosing just to accommodate tadalafil timing; if evening dosing of levothyroxine is being considered for other reasons, that decision should be made with a prescriber, since it changes the fasting window needed around the dose.

Co-medications that matter more than levothyroxine

The tadalafil-levothyroxine pair itself is low risk, but tadalafil has other interactions that are clinically significant and unrelated to thyroid status:

• Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate): absolutely contraindicated with tadalafil due to risk of severe hypotension.
• Alpha-blockers (tamsulosin, doxazosin, terazosin): combined use requires caution and, per the tadalafil label, patients should generally be stable on alpha-blocker therapy before starting tadalafil; higher tadalafil doses with non-selective alpha-blockers carry more hypotension risk.
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin): these can substantially raise tadalafil exposure. The tadalafil label specifies reduced maximum doses when a strong CYP3A4 inhibitor is co-prescribed; the exact adjusted dose should be confirmed against the current label rather than assumed.
• Warfarin: levothyroxine can affect the metabolism of vitamin K-dependent clotting factors, and starting or adjusting levothyroxine in a patient on warfarin generally warrants closer INR monitoring per thyroid society guidance. Tadalafil itself does not affect warfarin pharmacokinetics, but a three-drug regimen (tadalafil, levothyroxine, warfarin) is a reasonable trigger for a pharmacist medication review.

None of these interactions involve levothyroxine and tadalafil together; they involve tadalafil with a third drug, or levothyroxine with a third drug, that happens to be common in the same patient population.

Hypothyroidism and erectile dysfunction: why they show up together

Thyroid hormone influences vascular smooth muscle function, and both hypothyroidism and hyperthyroidism are associated with sexual dysfunction in the clinical literature, though exact prevalence figures vary across studies and populations and should not be treated as a fixed number. This overlap is the clinical reason these two drugs end up prescribed together, not evidence of an interaction between them. Some men see erectile function improve once thyroid hormone levels are normalized and no longer need a PDE5 inhibitor; others continue to need one even after their thyroid status is well controlled. Persistent erectile dysfunction after normalized thyroid function warrants its own evaluation for cardiovascular, hormonal (including testosterone), psychological, and medication-related causes, since ED has many contributors beyond thyroid status.

Over-replacement is the scenario to watch

If levothyroxine dosing runs too high, the resulting mild hyperthyroid state can raise resting heart rate and lower blood pressure through its own mechanism. Tadalafil independently causes a small reduction in blood pressure. In a patient who is inadvertently over-replaced, especially an older adult or someone with existing cardiovascular disease, the combined hemodynamic effect is a reasonable theoretical concern, even though it has not been studied as a formal interaction between these two drugs. The appropriate response is not to avoid tadalafil, but to correct the levothyroxine dose and confirm TSH is back in the target range set by the prescriber.

Special populations

Older adults. Hypothyroidism prevalence rises with age, and this is the population most likely to be prescribed both drugs together. The tadalafil label notes pharmacokinetic differences in older adults; ask the prescriber whether any dose adjustment applies based on the current label and the patient's renal and hepatic function, rather than assuming none is needed.

Renal impairment. The tadalafil label specifies reduced maximum doses in moderate-to-severe renal impairment. Levothyroxine dosing is not adjusted for renal function directly, though correcting hypothyroidism can improve some renal function markers in affected patients.

Hepatic impairment. Tadalafil exposure increases with moderate hepatic impairment and the label recommends a lower maximum dose; tadalafil has not been studied in severe hepatic impairment and is generally not recommended in that setting. Levothyroxine dosing is not adjusted for hepatic impairment.

Dose adjustments for renal or hepatic impairment should be confirmed against the current label and made by the prescribing clinician; this article does not provide individualized dosing.

Evidence-status interaction assessment

When to seek care rather than self-manage

Contact a prescriber promptly, or seek urgent care, for chest pain, fainting, an erection lasting more than four hours, palpitations with dizziness, or signs of thyroid over-replacement such as unexplained rapid heartbeat, tremor, or heat intolerance. These symptoms need direct evaluation rather than self-adjustment of either medication.

Patient counseling summary

Levothyroxine goes first, in the morning, on an empty stomach, separated from food, coffee, calcium, and iron by the interval a pharmacist recommends. Tadalafil can be taken whenever it is needed, or at a consistent time each day for the low-dose regimen, without regard to the levothyroxine dosing window. Do not move levothyroxine to a different time of day solely to accommodate tadalafil. Report symptoms of thyroid over-replacement at any follow-up visit. If erectile dysfunction persists after thyroid levels are normalized, tadalafil can generally continue alongside levothyroxine without additional monitoring specific to the combination, though the underlying cause of ongoing ED should still be reviewed with a clinician.

References

1. FDA prescribing information for tadalafil (Cialis).
2. FDA prescribing information for levothyroxine sodium.

The supporting documentation for this content referenced multiple PubMed citations with specific quantitative data (including exact percentages for AUC changes, absorption reduction, and ED prevalence). During this revision, these citations could not be confirmed against their source documents, and independent searches of the primary literature failed to locate matching studies. To avoid presenting unconfirmed figures, this draft presents the relevant claims in qualitative terms and identifies them for verification using the primary literature or current FDA labeling prior to final publication.